Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof
The invention concerns a composition containing at least an oxazolin, optionally combined with at least a compound such as a metalloprotease inhibitor, a PKC inhibitor, an anti-inflammatory agent, a soothing agent, an immunosuppressor, an ion chelating agent, an alkanolamide, an oxazolidinone and a carbamic acid derivative. The invention also concerns the use of such a composition as medicine, in particular for preventing or treating skin pathologies of allergic and/or inflammatory and/or irritative origin or resulting from a danger signal. The invention further concerns a method for cosmetic treatment of sensitive, irritated, intolerant, allergy-prone, ageing skin and/or mucosa exhibiting skin barrier disorder, or exhibiting non-pathological immunologic imbalance, which consists in applying such composition on the skin and/or mucosa.
1. A method for treating a condition or disease selected from the group consisting of irritative dermatitis, atopic dermatitis, inflammatory dermatitis, allergic skin, sensitive skin, reactive skin, irritated skin and aging skin, said method comprising:
applying to a person in need thereof a composition comprising a retinoid and an oxazoline as an active ingredient,
wherein said oxazoline is selected from the group consisting of 2-undecyl-4-hydroxymethyl-4-methyl-1,3-oxazoline, 2-undecyl-4,4-dimethyl-1,3-oxazoline, (E)-4,4-dimethyl-2-heptadec-8-enyl-1,3-oxazoline, 4-hydroxymethyl-4-methyl-2-heptadecyl-1,3-oxazoline, (E)-4-hydroxymethyl-1-4-methyl-2-heptadec-8-enyl-1,3-oxazoline, and 2-undecyl-4-ethyl-4-hydroxymethyl-1,3-oxazoline.
2. The method according to claim 1 , wherein said disease or condition is from the allergenic and/or irritant character of a composition or a perfume.
3. The method according to claim 1 , wherein said oxazoline is 2-undecyl-4,4-dimethyl-1,3-oxazoline of the formula;
4. The method according to claim 1 , wherein said composition is a cosmetic or pharmaceutical composition comprising about 0.001% to about 10% by weight of the oxazoline and a cosmetically or pharmaceutically acceptable excipient.